Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fiasp vs Insulin Aspart in Type 2 Diabetes
NCT01819129Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2013
- Primary completion
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Sep 2013; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01819129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01819129.